Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-29T05:30:13.974Z Has data issue: false hasContentIssue false

Chapter 3 - Advances in ART Pharmacology: Drug Delivery Systems and the Pipeline

Published online by Cambridge University Press:  02 March 2020

By
Colin M Howles
Edited by
Alice D. Domar ,
Denny Sakkas  and
Thomas L. Toth
Alice D. Domar
Affiliation:
Boston IVF, Waltham, MA
Denny Sakkas
Affiliation:
Boston IVF, Waltham, MA
Thomas L. Toth
Affiliation:
Boston IVF, Waltham, MA
Get access

Summary

Since the very early years (1969–1978) of human IVF, Patrick Steptoe and Robert Edwards were utilizing a range of pharmaceutical agents for ovarian stimulation, ovulation induction, and luteal phase support (e.g., urinary gonadotrophins, chorionic gonadotrophin, clomiphene citrate, progesterone). However, in spite of their efforts with these agents, their breakthrough pregnancy following ovarian stimulation was sadly an ectopic.

Type
Chapter
Information
Patient-Centered Assisted Reproduction
How to Integrate Exceptional Care with Cutting-Edge Technology
 , pp. 23 - 38
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Elder, K, Johnson, MH. The Oldham Notebooks: An Analysis of the Development of IVF 1969–1978. I. Introduction, Materials and Methods. Reprod Biomed Soc Online. 2015; 1(1): 3–8.Google Scholar
Elder, K, Johnson, MH. The Oldham Notebooks: An Analysis of the Development of IVF 1969–1978. II. The Treatment Cycles and Their Outcomes. Reprod Biomed Soc Online. 2015; 1(1): 9–18.Google Scholar
Steptoe, PC, Edwards, RG. Reimplantation of a Human Embryo with Subsequent Tubal Pregnancy. Lancet. 1976; 1(7965): 880–2.Google Scholar
Steptoe, PC, Edwards, RG. Birth After the Reimplantation of a Human Embryo. Lancet. 1978; 2(8085): 366.CrossRefGoogle ScholarPubMed
Cohen, J, Trounson, A, Dawson, K, et al. The Early Days of IVF Outside the UK. Hum Reprod Update. 2005; 11(5): 439–59.Google Scholar
Edwards, RG, Lobo, R, Bouchard, P. Time to Revolutionize Ovarian Stimulation. Hum Reprod. 1996; 11(5): 917–19.Google Scholar
Alper, MM, Fauser, BC Ovarian Stimulation Protocols for IVF: Is More Better Than Less? Reprod Biomed Online. 2017; 34(4): 345–53.Google Scholar
Drakopoulos, P, Blockeel, C, Stoop, D, et al. Conventional Ovarian Stimulation and Single Embryo Transfer for IVF/ICSI. How Many Oocytes Do We Need to Maximize Cumulative Live Birth Rates After Utilization of All Fresh and Frozen Embryos? Hum Reprod. 2016; 31(2): 370–6.Google Scholar
Polyzos, NP, Drakopoulos, P, Parra, J, et al. Cumulative Live Birth Rates According to the Number of Oocytes Retrieved After the First Ovarian Stimulation for in Vitro Fertilization/Intracytoplasmic Sperm Injection: A Multicenter Multinational Analysis Including ~15,000 Women. Fertil Steril. 2018; 110(4): 661–70.Google Scholar
Howles, CM. Genetic Engineering of Human FSH (Gonal-F). Hum Reprod Update. 1996; 2: 172–91.CrossRefGoogle ScholarPubMed
Ludwig, M, Felberbaum, RE, Diedrich, K, Lunenfeld, B. Ovarian Stimulation: From Basic Science to Clinical Application. Reprod Biomed Online. 2002; 5 Suppl 1: 73–86.Google Scholar
Lunenfeld, B. Historical Perspectives in Gonadotrophin Therapy. Hum Reprod Update. 2004; 10: 453–67.Google Scholar
DiMasi, JA. Assessing Pharmaceutical Research and Development Costs. JAMA Intern Med. 2018; 178(4): 587.Google Scholar
Howles, CM. The Development of Ovarian Stimulation for IVF in in-Vitro Fertilisation: The Pioneers’ History. In: Kovacs, G, Brinsden, P. (eds.). UK: Cambridge University Press. 2018; 202–7.Google Scholar
Kushnir, VA, Barad, DH, Albertini, DF, Darmon, SK, Gleicher, N. Systematic Review of Worldwide Trends in Assisted Reproductive Technology 2004–2013. Reprod Biol Endocrinol. 2017; 15(1): 6.CrossRefGoogle ScholarPubMed
ESHRE conference. (2018) ICMART report. Online article. www.sciencedaily.com/releases/2018/07/180703084127.htmGoogle Scholar
Howles, CM, Saunders, H, Alam, V, Engrand, P. FSH Treatment Guidelines Clinical Panel. Predictive Factors and a Corresponding Treatment Algorithm for Controlled Ovarian Stimulation in Patients Treated with Recombinant Human Follicle Stimulating Hormone (Follitropin Alfa) During Assisted Reproduction Technology (ART) Procedures. An Analysis of 1378 Patients. Curr Med Res Opin. 2006.CrossRefGoogle Scholar
DiMasi, JA, Grabowski, HG, Hansen, RW. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. J Health Econ. 2016; 47: 20–33.Google Scholar
Office of Health Economics. The R&D Cost of a New Medicine. Online article. www.ohe.org/publications/rd-cost-new-medicineGoogle Scholar
Agrawal, R, West, C, Conway, GS, Page, ML, Jacobs, HS. Pregnancy After Treatment with Three Recombinant Gonadotropins. Lancet. 1997; 349: 29–30.Google Scholar
Humaidan, P, Chin, W, Rogoff, D, et al. ESPART Study Investigators. Efficacy and Safety of Follitropin Alfa/Lutropin Alfa in ART: A Randomized Controlled Trial in Poor Ovarian Responders. Hum Reprod. 2017; 32(3): 544–55.Google Scholar
de Mora, F, Fauser, BCJM. Biosimilars to Recombinant Human FSH Medicines: Comparable Efficacy and Safety to the Original Biologic. Reprod Biomed Online. 2017;35(1): 81–6.Google Scholar
FDA Questions & Answers on Biosimilar Development. (2018). Online article. www.fda.gov/downloads/drugs/guidances/ucm444661.pdfGoogle Scholar
Blackstone and Fuhr Joseph. (2013). Let’s See How Biosimilars Are Developed. Online article. www.pfizerbiosimilars.com/biosimilars-developmentGoogle Scholar
Howles, CM, Loumaye, E, Giroud, D, Luyet, G. Multiple Follicular Development and Ovarian Steroidogenesis Following Subcutaneous Administration of a Highly Purified Urinary FSH Preparation in Pituitary Desensitized Women Undergoing IVF: A Multicentre European Phase III Study. Hum Reprod. 1994; 9(3): 424–30.Google Scholar
Quintans, CJ, Donaldson, MJ, Blanco, LA, Pasqualini, RS. Empty Follicle Syndrome Due to Human Errors: Its Occurrence in an in-Vitro Fertilization Programme. Hum Reprod. 1998; 13(10): 2703–5.Google Scholar
Markle, RL, King, PJ, Martin, DB. Characteristics of a Successful Human Chorionic Gonadotropin (hCG) Administration in Assisted Reproduction. Fertil Steril. 2002; 78(Suppl 1): S71–2.Google Scholar
Snaifer, E, Hugues, JN, Poncelet, C, Sifer, C, Pasquier, M, Cedrin-Durnerin, I. “Empty Follicle Syndrome” After Human Error: Pregnancy Obtained After Repeated Oocyte Retrieval in a Gonadotropin-Releasing Hormone Antagonist Cycle. Fertil Steril. 2008; 90(3): 850.e13–15.Google Scholar
Weiss, N. Gonadotrophin Products: Empowering Patients to Choose the Product That Meets Their Needs. Reprod Biomed Online. 2007; 15: 31–7.Google Scholar
Saunders, H, de la Fuente Bitaine, L, Eftekhar, C, et al. Functionality of a Novel Follitropin Alfa Pen Injector: Results from Human Factor Interactions by Patients and Nurses. Expert Opin Drug Deliv. 2018; 15(6): 549–58.Google Scholar
Zitoun, P, Parikh, J, Nijs, M, Zhang, W, Levy-Toledano, R. Tang, B. Analysis of Patient and Nurse Preferences for Self-Administered FSH Injection Devices in Select European Markets. Int J Womens Health. 2019; 11: 11–21.Google Scholar
Sedbon, E, Wainer, R, Perves, C. Quality of Life of Patients Undergoing Ovarian Stimulation with Injectable Drugs in Relation to Medical Practice in France. Reprod Biomed Online. 2006; 12, 298–303.CrossRefGoogle ScholarPubMed
Huisman, D, Raymakers, X, Hoomans, EH. Understanding the Burden of Ovarian Stimulation: Fertility Expert and Patient Perceptions. Reprod Biomed Online. 2009; 19 Suppl 2: 5–10.CrossRefGoogle ScholarPubMed
Verberg, MF, Eijkemans, MJ, Heijnen, EM, et al. Why Do Couples Drop-out from IVF Treatment? A Prospective Cohort Study. Hum Reprod. 2008; 23(9): 2050–5.Google Scholar
Brod, M, Verhaak, CM, Wiebinga, CJ, Gerris, J, Hoomans, EH. Improving Clinical Understanding of the Effect of Ovarian Stimulation on Women’s Lives. Reprod Biomed Online. 2009; 18(3): 391–400.Google Scholar
Fares, FA, Suganuma, N, Nishimori, K, et al. Design of a Long-Acting Follitropin Agonist by Fusing the C-Terminal Sequence of the Chorionic Gonadotropin Beta Subunit to the Follitropin Beta Subunit. Proc Natl Acad Sci USA. 1992; 89: 4304–8.CrossRefGoogle Scholar
Beckers, NG, Macklon, NS, Devroey, P, Platteau, P, Boerrigter, PJ, Fauser, BC. First Live Birth After Ovarian Stimulation Using a Chimeric Long-Acting Human Recombinant Follicle-Stimulating Hormone (FSH) Agonist (recFSH-CTP) For in Vitro Fertilization. Fertil Steril. 2003; 79(3): 621–3.Google Scholar
Merck & Co Annual Report for the Fiscal Year Ended Dec 31 2015 (filed with the Securities and Exchange Commission in February 2016). Online report. www.sec.gov/Archives/edgar/data/310158/000031015816000063/mrk1231201510k.htmGoogle Scholar
le Cotonnec, JY, Porchet, HC, Beltrami, V, Khan, A, Toon, S, Rowland, M. Clinical Pharmacology of Recombinant Human Follicle-Stimulating Hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril. 1994; 61(4): 669–78.Google Scholar
Scholtes, MC, Schnittert, B, van Hoogstraten, D, Verhoeven, HC, Zrener, A, Warne, DW. A Comparison of 3-Day and Daily Follicle-Stimulating Hormone Injections on Stimulation Days 1–6 in Women Undergoing Controlled Ovarian Hyperstimulation. Fertil Steril. 2004; 81: 996–1001.Google Scholar
Sharma, V, Williams, J, Collins, W, Riddle, A, Mason, B, Whitehead, M. A Comparison of Treatments with Exogenous FSH to Promote Folliculogenesis in Patients with Quiescent Ovaries Due to the Continued Administration of an LH-RH Agonist. Hum Reprod. 1987; 2: 553–6.Google Scholar
ClinicalTrials.gov Identifier: NCT03019575. Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH). Online article. https://clinicaltrials.gov/ct2/show/NCT03019575Google Scholar
Howles, CM, Tanaka, T, Matsuda, T. Management of Male Hypogonadotrophic Hypogonadism. Endocr J. 2007; 54(2): 177–90.Google Scholar
Olsson, H, Sandstrom, R, Grundemar, L. Different Pharmacokinetic and Pharmacodynamic Properties of Recombinant Follicle-Stimulating Hormone (rFSH) Derived from a Human Cell Line Compared with rFSH from a Non-Human Cell Line. J Clin Pharmacol. 2014; 54: 1299–307.Google Scholar
Arce, JC, Andersen, AN, Fernández-Sánchez, M, et al. Ovarian Response to Recombinant Human Follicle-Stimulating Hormone: A Randomized, Antimüllerian Hormone-Stratified, Dose-Response Trial in Women Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection. Fertil Steril. 2014; 102: 1633–40.CrossRefGoogle ScholarPubMed
Haute Autorité de Santé. Online article. https://www.has-sante.fr/upload/docs/application/pdf/2017-09/rekovelle_summary_ct15912.pdfGoogle Scholar
Abd-Elaziz, K, Duijkers, I, Stöckl, L, et al. A New Fully Human Recombinant FSH (Follitropin Epsilon): Two Phase I Randomized Placebo and Comparator-Controlled Pharmacokinetic and Pharmacodynamic Trials. Hum Reprod. 2017; 7: 1–9.Google Scholar
Millar, RP, Zhu, YF, Chen, C, Struthers, RS. Progress Towards the Development of Non-Peptide Orally-Active Gonadotropin-Releasing Hormone (GnRH) Antagonists: Therapeutic Implications. Br Med Bull. 2000; 56(3): 761–72.Google Scholar
ASRM fact sheet Endometriosis. Online article. www.reproductivefacts.org/news-and-publications/patient-fact-sheets-and-booklets/documents/fact-sheets-and-info-booklets/endometriosis-bookletGoogle Scholar
Clarivate Analytics. (2018). Sales Forecasts Rise for AbbVie’s Elagolix Following Expected Approval in Endometriosis. Online article. https://clarivate.com/blog/life-sciences-connect/sales-forecasts-rise-for-abbvies-elagolix-following-expected-approval-in-endometriosis/Google Scholar
Vercellini, P, Viganò, P, Barbara, G, Buggio, L, Somigliana, E. “Luigi Mangiagalli” Endometriosis Study Group. Elagolix for Endometriosis: All That Glitters Is Not Gold. Hum Reprod. 2018.Google Scholar
Paulson, RJ. At Last, an Orally Active Gonadotropin-Releasing Hormone Antagonist. Fertil Steril. 2019; 111(1): 30–1.Google Scholar
Arey, BJ, Deecher, DC, Shen, ES, et al. Identification and Characterization of a Selective, Nonpeptide Follicle-Stimulating Hormone Receptor Antagonist. Endocrinology. 2002; 143.Google Scholar
Guo, T, Adang, AE, Dolle, RE, et al. Small Molecule Biaryl FSH Receptor Agonists. Part 1: Lead Discovery Via Encoded Combinatorial Synthesis. Bioorg Med Chem Lett. 2004; 14(7): 1713–16.Google Scholar
Maclean, D, Holden, F, Davis, AM, et al. Agonists of the Follicle Stimulating Hormone Receptor from an Encoded Thiazolidinone Library. J Comb Chem. 2004; 6.Google Scholar
Howles, CM, Arkinstall, S. Developing new therapeutics for ART: recombinant DNA technology and beyond. In: Textbook of Assisted Reproductive Techniques: Laboratory and Clinical Perspectives Edition: 1. Gardner, DK, Weissman, A, Howles, CM, Shoham, Z (eds.). Taylor & Francis.Google Scholar
Palmer, SS, McKenna, S, Arkinstall, S. Discovery of New Molecules for Future Treatment of Infertility. Reprod Biomed Online. 2005; 10 Suppl 3: 45–54.Google Scholar
Nataraja, SG, Yu, HN, Palmer, SS. Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone Receptors. Front Endocrinol (Lausanne). 2015; 6: 142.Google Scholar
van de Lagemaat, R, Timmers, CM, Kelder, J, van Koppen, C, Mosselman, S, Hanssen, RG. Induction of Ovulation by a Potent, Orally Active, Low Molecular Weight Agonist (Org 43553) of the Luteinizing Hormone Receptor. Hum Reprod. 2009; 24(3): 640–8.Google Scholar
Mannaerts, B. Novel FSH and LH agonists. From anovulation to assisted reproduction. Proceedings of the Fourth World Congress on Ovulation. In: Filicori, M (ed.) 2004; 157–72.Google Scholar
Howles, CM, Macnamee, MC, Edwards, RG. Follicular Development and Early Luteal Function of Conception and Non-Conceptional Cycles After Human in-Vitro Fertilization: Endocrine Correlates. Hum Reprod. 1987; 2(1): 17–21.Google Scholar
Jones, HW, Jr., Jones, GS, Andrews, MC, et al. The Program for in Vitro Fertilization at Norfolk. Fertil Steril 1982; 38: 14–21.Google Scholar
van der Linden, M, Buckingham, K, Farquhar, C, Kremer, JA, Metwally, M. Luteal Phase Support for Assisted Reproduction Cycles. Cochrane Database Syst Rev. 2015; CD009154.Google Scholar
Weissman, A. A Survey on Luteal-Phase Support. (2018). ISARG Conference, Tel Aviv, Israel. Online article. http://cme-utilities.com/mailshotcme/SARG/Presentations/1200_Weissman_B_Tue.pdfGoogle Scholar
Humaidan, P, Bredkjaer, HE, Bungum, L, et al. GnRH Agonist (Buserelin) or hCG for Ovulation Induction in GnRH Antagonist IVF/ICSI Cycles: A Prospective Randomized Study. Hum Reprod. 2005; 20: 1213–20.Google Scholar
Tournaye, H, Sukhikh, GT, Kahler, E, Griesinger, G. A Phase III Randomized Controlled Trial Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Support in in Vitro Fertilization. Hum Reprod. 2017; 32(10): 2152.Google Scholar
Griesinger, G, Blockeel, C, Sukhikh, GT, et al. Oral Dydrogesterone Versus Intravaginal Micronized Progesterone Gel for Luteal Phase Support in IVF: A Randomized Clinical Trial. Hum Reprod. 2018; 33(12): 2212–21.Google Scholar
Griesinger, G, Blockeel, C, Kahler, E, Pexman-Fieth, C. Use of Oral Dydrogesterone for Luteal Phase Support in Fresh IVF Cycles Is Associated with an Increase in Live Birth Rate: An Integrated Individual Patient Data Analysis of the Lotus Phase III Trial Program. Fertil Steril. 2018; 110(4): e90.Google Scholar
Labarta, E, Mariani, G, Holtmann, N, Celada, P, Remohí, J, Bosch, E. Low Serum Progesterone on the Day of Embryo Transfer Is Associated with a Diminished Ongoing Pregnancy Rate in Oocyte Donation Cycles After Artificial Endometrial Preparation: A Prospective Study. Hum Reprod. 2017; 32(12): 2437–42.Google Scholar
Alsbjerg, B, Thomsen, L, Elbaek, HO, et al. Progesterone Levels on Pregnancy Test Day After Hormone Replacement Therapy-Cryopreserved Embryo Transfer Cycles and Related Reproductive Outcomes. Reprod Biomed Online. 2018; 37(5): 641–7.Google Scholar
Alsbjerg, B, Polyzos, NP, Elbaek, HO, Povlsen, BB, Andersen, CY, Humaidan, P. Increasing Vaginal Progesterone Gel Supplementation After Frozen-Thawed Embryo Transfer Significantly Increases the Delivery Rate. Reprod Biomed Online. 2013; 26(2): 133–7.Google Scholar
Griesinger, G, Blockeel, C, Tournaye, H. Oral Dydrogesterone for Luteal Phase Support in Fresh in Vitro Fertilization Cycles: A New Standard? Fertil Steril. 2018; 109(5): 756–62.Google Scholar
Visnova, H, Tournaye, H, Humberstone, A, Terrill, P, Macgregor, L, Loumaye, E. A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer. Fertil Steril. 2018; 110(4): e45.Google Scholar
Howles, CM. Recombinant Gonadotrophins in Reproductive Medicine: The Gold Standard of Today. Reprod Biomed Online. 2006; 12: 11–13.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×